REDWOOD CITY, Calif., Oct. 19 /PRNewswire/ — Ingenuity®
Systems, the leading provider of information solutions for life
science researchers, and TransMed Systems, a translational medicine
software and services company, today announced an integration
between IPA® software and XB Bio-Integration Suite (XB-BIS).
Researchers can now easily take pre-clinical and clinical
data that is managed and statistically analyzed by XB-BIS, directly
into IPA®, which is used by researchers to model, analyze, and
explore various types of ‘omics data to gain a deeper understanding
of complex biological systems.
The software integration supports academic and commercial
researchers who are studying how genes affect the way individuals
respond to drug treatments. Joint customers will have a clear
workflow to analyze pre-clinical and clinical data in the context
of signaling and metabolic pathways, networks, and cellular
processes available in IPA. This approach helps researchers move
rapidly and confidently from hypothesis generation to validation
experiments.
Nick Berens, CEO, TransMed Systems, said, “The integration
between XB-BIS and IPA will enable physicians, clinicians and
researchers to integrate the latest biological content, pathways
and molecular networks into their translational medicine and
research. These enhanced capabilities will allow for more
timely and informed treatment strategies and practices and improve
personalized medicine.”
Doug Bassett, Ph.D., CSO and CTO, Ingenuity Systems, stated,
“Personalized medicine requires the ability to quickly translate
large amounts of data into meaningful biological information.
We’re very pleased that our partnership with TransMed will
provide a streamlined platform from which researchers and
clinicians will be able to collect and analyze data, link genotypes
to phenotypes, identify potential biomarkers, generate powerful and
informed hypotheses, and understand the molecular d
‘/>”/>